This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Development of a computational histology artificial intelligence (CHAI)–powered predictive biomarker for first-line chemotherapy intensification in metastatic colorectal cancer (mCRC) and validation in prospective randomized phase III trials (RCT).
Paolo Ciracì et al.. 2026.
-
Implementing a centralized navigator-led and AI-assisted platform to improve lung cancer screening rates and early detection: A 6-year health system analysis.
Jun Zhang et al.. 2026.
-
Gaps in patient-facing information on artificial intelligence in cancer care: A cross-sectional analysis.
Pearl Subramanian et al.. 2026.
Weekly News Brief: June 1–5, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of June 1–5, 2026.
This week’s brief includes coverage from AI-focused presentations at the 2026 ASCO Annual Meeting.
To learn more about a computational histology AI biomarker, read "CHAI Biomarker Guides Upfront Chemotherapy Intensification Choice in mCRC," or see the abstract.
For more information on OSF HealthCare's AI-supported lung cancer screening program, read "AI-Assisted Multistep Lung Cancer Screening Program Boosts Uptake Beyond National Averages," or see the abstract.
And, to learn more about patient-facing AI resource quality, read "How Well Do Patient-Facing Resources on AI and Cancer Measure Up?," or see the abstract.
For more coverage from the 2026 ASCO Annual Meeting, visit ascoai.org/meetings.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.